Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

Author(s):

Panelists discuss how the interim results from the phase 3 ADRIATIC trial demonstrate significant overall survival and progression-free survival benefits for patients with limited-stage small cell lung cancer following concurrent chemoradiotherapy, highlighting the potential clinical relevance of durvalumab in improving life expectancy and its mechanisms of synergy within the tumor microenvironment.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

Now Viewing

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

EP: 5.Defining Platinum Sensitivity in SCLC

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

Video content above is prompted by the following:

Dr Leal: Please discuss the interim results from the phase 3 ADRIATIC trial, which evaluated durvalumab in patients with limited-stage small cell lung cancer (LS-SCLC) who did not experience disease progression following concurrent chemoradiotherapy (cCRT) vs placebo after cCRT.

Spigel D et al. Plenary Session 2024 ASCO Annual Meeting. LBA5; Spigel DR et al. J Clin Oncol. 2024;42(17 suppl):abstract LBA5. https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5

Dr Sen: How might the statistically significant overall survival and progression-free survival outcomes reported in ADRIATICtranslate into a clinically relevant improvement in life expectancy for your patients with LS-SCLC that has not progressed after cCRT?